These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24800949)

  • 1. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
    Tan AR; Dowlati A; Stein MN; Jones SF; Infante JR; Bendell J; Kane MP; Levinson KT; Suttle AB; Burris HA
    Br J Cancer; 2014 May; 110(11):2647-54. PubMed ID: 24800949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Tan AR; Dowlati A; Jones SF; Infante JR; Nishioka J; Fang L; Hodge JP; Gainer SD; Arumugham T; Suttle AB; Dar MM; Lager JJ; Burris HA
    Oncologist; 2010; 15(12):1253-61. PubMed ID: 21147873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
    Burris HA; Dowlati A; Moss RA; Infante JR; Jones SF; Spigel DR; Levinson KT; Lindquist D; Gainer SD; Dar MM; Suttle AB; Ball HA; Tan AR
    Mol Cancer Ther; 2012 Aug; 11(8):1820-8. PubMed ID: 22679111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
    Inada-Inoue M; Ando Y; Kawada K; Mitsuma A; Sawaki M; Yokoyama T; Sunakawa Y; Ishida H; Araki K; Yamashita K; Mizuno K; Nagashima F; Takekura A; Nagamatsu K; Sasaki Y
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):673-83. PubMed ID: 24464355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
    Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
    Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
    Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
    Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
    Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
    Kerklaan BM; Lolkema MP; Devriese LA; Voest EE; Nol-Boekel A; Mergui-Roelvink M; Langenberg M; Mykulowycz K; Stoebenau J; Lane S; Legenne P; Wissel P; Smith DA; Giantonio BJ; Schellens JH; Witteveen PO
    Br J Cancer; 2015 Sep; 113(5):706-15. PubMed ID: 26291057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
    Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
    Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
    Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J
    Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
    Chien AJ; Illi JA; Ko AH; Korn WM; Fong L; Chen LM; Kashani-Sabet M; Ryan CJ; Rosenberg JE; Dubey S; Small EJ; Jahan TM; Hylton NM; Yeh BM; Huang Y; Koch KM; Moasser MM
    Clin Cancer Res; 2009 Sep; 15(17):5569-75. PubMed ID: 19706807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
    J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
    Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.
    Wisinski KB; Tevaarwerk AJ; Burkard ME; Rampurwala M; Eickhoff J; Bell MC; Kolesar JM; Flynn C; Liu G
    Clin Cancer Res; 2016 Jun; 22(11):2659-67. PubMed ID: 27026198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
    Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
    Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
    Narayanan S; Lam A; Vaishampayan U; Harshman L; Fan A; Pachynski R; Poushnejad S; Haas D; Li S; Srinivas S
    Clin Genitourin Cancer; 2016 Oct; 14(5):432-437. PubMed ID: 27068017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.